Company intelligence / Profile preview

38TERA

Unknown, Unknown, United States38tera.com ↗

Ownership: Private
Development stage: Commercial

Overview

38TERA has launched Daily Microbiome Nutrition (DMN™), a prebiotic supplement formulated with clinically validated ingredients at therapeutic doses. The product is designed to nourish healthy gut bacteria, support bowel regularity, improve gastrointestinal comfort, and promote overall gut microbiome health. Clinical studies cited by the company show increases in beneficial bacteria like Akkermansia and Bifidobacterium with their core ingredient Solnul® resistant potato starch[7].

Therapeutic areas: Gastroenterology
Modalities: Prebiotic supplementDietary fiber (Resistant starch)Polyphenol-based supplement
Industry: Food & Nutrition

Drug pipeline

1 asset

Daily Microbiome Nutrition

Commercial

Indications: Digestive health, Gut microbiome support

Partnerships

No major pharmaceutical or biotech partnerships disclosed.

Beyond the preview

Go deeper on 38TERA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 38TERA.

Explore the full profile